VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program
“This partnership brings together two highly complementary technologies to create a new class of bispecific ADCs,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “Bispecific ADCs represent a powerful opportunity to address difficult-to-treat solid tumors, and this collaboration fits squarely within our mission to drive innovation through targeted partnerships. Strategic collaborations will continue to be a mainstay in VERAXA’s pipeline growth strategy, and today’s announcement marks the second major initiative within the past six months, following our first radiopharmaceutical alliance late last year. We look forward to advancing this discovery program alongside OmniAb and deliver novel therapeutic solutions for patients with significant unmet needs.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines